Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

100%(4 trials)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

NCT03469934

completedphase_2

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

NCT02920021

completedphase_2

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT03533751

completedphase_2

Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

NCT03614923

Clinical Trials (4)

Showing 4 of 4 trials

NCT03469934Phase 2

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

Completed

NCT02920021Phase 2

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

Completed

NCT03533751Phase 2

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Completed

NCT03614923Phase 2

Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4